Chang W Y, Wang L Y, Chuang W L, Chen S C, Lu S N, You S L
Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):128-31. doi: 10.1111/j.1440-1746.1992.tb00948.x.
To investigate the positive rates of antibodies to hepatitis C virus (anti-HCV) in Chinese cirrhotic patients with or without hepatocellular carcinoma and to evaluate the influence of blood transfusion on the prevalence of anti-HCV in such patients, a longitudinal study in 30 cirrhotic patients (17 combined with hepatocellular carcinoma) was carried out. Five patients (16.7%) were anti-HCV positive before transfusion. The positive rate of anti-HCV in HBsAg-positive patients and HBsAg-negative patients was 9.5% (2/21) and 33.3% (3/9), respectively. The positive rates in cirrhotic patients with or without hepatocellular carcinoma were 23.5% (4/17) and 7.7% (1/13), respectively. The positive rate of anti-HCV increased significantly after multitransfusion, and the estimated infectivity of blood products was 6.1 patients per 1000 units of blood products. It was concluded that the aetiological role of hepatitis C virus on liver cirrhosis and hepatocellular carcinoma in the endemic area of hepatitis B virus is not so important as in Western countries, and transfusion might result in an overestimated pathogenic effect of hepatitis C virus in cirrhotic patients and patients with hepatocellular carcinoma.
为调查中国肝硬化患者（无论有无肝细胞癌）丙型肝炎病毒抗体（抗-HCV）的阳性率，并评估输血对这类患者抗-HCV流行率的影响，对30例肝硬化患者（17例合并肝细胞癌）进行了一项纵向研究。5例患者（16.7%）输血前抗-HCV呈阳性。HBsAg阳性患者和HBsAg阴性患者的抗-HCV阳性率分别为9.5%（2/21）和33.3%（3/9）。有或无肝细胞癌的肝硬化患者的阳性率分别为23.5%（4/17）和7.7%（1/13）。多次输血后抗-HCV阳性率显著升高，估计血液制品的感染性为每1000单位血液制品6.1例患者。得出的结论是，在乙肝病毒流行地区，丙型肝炎病毒对肝硬化和肝细胞癌的病因学作用不如西方国家重要，输血可能导致丙型肝炎病毒在肝硬化患者和肝细胞癌患者中的致病作用被高估。
